Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 47% Improvement Relative Risk c19hcq.org Signes-Costa et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 5,847 patients in multiple countries Lower mortality with HCQ (p=0.00046) Signes-Costa et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.11.012 Favors HCQ Favors control
Prevalence and 30-day mortality in hospitalized patients with COVID-19 and prior lung diseases
Signes-Costa et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.11.012
Signes-Costa et al., Prevalence and 30-day mortality in hospitalized patients with COVID-19 and prior lung diseases, Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.11.012
Dec 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
47% lower mortality with HCQ/CQ. Retrospective 1,271 patients with lung disease in Canada, China, Cuba, Ecuador, Germany, Italy and Spain, 83% treated with HCQ/CQ.
Multivariable Cox regression HCQ/CQ mortality hazard ratio HR 0.53, p < 0.001.
risk of death, 47.0% lower, RR 0.53, p < 0.001, treatment 4,854, control 993, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Signes-Costa et al., 16 Dec 2020, retrospective, multiple countries, peer-reviewed, 28 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Arch Bronconeumol. 2021;57(S2):13–20 www.archbronconeumol.org Original Article Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases Jaime Signes-Costa a,∗ , Iván J. Núñez-Gil b , Joan B. Soriano c , Ramón Arroyo-Espliguero d , Charbel Maroun Eid e , Rodolfo Romero f , Aitor Uribarri g , Inmaculada Fernández-Rozas h , Marcos García Aguado i , Víctor Manuel Becerra-Muñoz j , Jia Huang k , Martino Pepe l , Enrico Cerrato m , Sergio Raposeiras n , Adelina Gonzalez o , Francisco Franco-Leon p , Lin Wang b , Emilio Alfonso q , Fabrizio Ugo r , Juan Fortunato García-Prieto s , Gisela Feltes t , Mohammad Abumayyaleh u , Carolina Espejo-Paeres v , Jorge Jativa w , Alvaro López Masjuan x , Carlos Macaya b , Juan A. Carbonell Asíns y , Vicente Estrada b , On behalf of HOPE COVID-19 investigators a Hospital Clínico Universitario, INCLIVA, Universidad de Valencia, Valencia, Spain Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain c Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain d Hospital Universitario Guadalajara, Guadalajara, Spain e Hospital Universitario La Paz, Instituto de Investigacion, Hospital Universitario La Paz (IdiPAZ), Madrid, Spain f Hospital Universitario Getafe, Madrid, Spain g Hospital Clínico Universitario de Valladolid, Valladolid, Spain h Hospital Severo Ochoa, Leganés, Spain i Hospital Universitario Puerta de Hierro, Majadahonda, Spain j Unidad de Gestión Clínica Área del Corazón, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, CIBERCV, Málaga, Spain k The Second People’s Hospital of Shenzhen, Shenzhen, China l Azienda ospedaliero-universitaria consorziale policlinico di Bari, Italy m San Luigi Gonzaga University Hospital, Rivoli, Turin, Italy n University Hospital Álvaro Cunqueiro, Vigo, Spain o Hospital Universitario Infanta Sofia, San Sebastián de los Reyes, Madrid, Spain p Hospital General del norte de Guayaquil IESS Los Ceibos, Guayaquil, Ecuador q Instituto de Cardiología y Cirugía Cardiovascular, Havana, Cuba r Sant’Andrea Hospital, Verdelli, Italy s Hospital Manises, Valencia, Spain t Hospital Nuestra Señora de América, Madrid, Spain u First Department of Medicine, Medical Faculty Mannheim, University Heidelberg, DZHK (German Center for Cardiovascular Research), Partner Site, Heidelberg-Mannheim, Mannheim, Germany v Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain w Hospital de Especialidades de las Fuerzas Armadas N1, Quito, Ecuador x Hospital Universitario Juan Ramón Jiménez, Huelva, Spain y Bioinformatics and Biostatisctics Unit, INCLIVA, Valencia, Spain b a r t i c l e i n f o Article history: Received 27 August 2020 Accepted 19 November 2020 Available online 16 December 2020 Keywords: COVID-19 a b s t r a c t Introduction: Patients with pre-existing respiratory diseases in the setting of COVID-19 may have a greater risk of severe complications and even death. Methods: A retrospective, multicenter, cohort study with 5847 COVID-19 patients admitted to hospitals. Patients were separated in two groups, with/without previous lung disease. Evaluation of factors associated with survival and secondary composite..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit